Introduction {#s1}
============

It is estimated that 439 million people worldwide will develop type 2 diabetes by the year 2030 ([@B1]). Diabetes and its associated complications contribute to escalating social and economic burdens on patients, families, and health care systems. A major challenge in caring for patients with diabetes is managing risk factors associated with the development of cardiovascular disease (CVD) and chronic kidney disease (CKD). These complications are important contributors to the higher mortality rates seen in individuals with diabetes.

Identifying factors that predict mortality in patients with type 2 diabetes is important to improve outcomes and prolong life. The African American population is relatively understudied, and it is critical to perform analyses in this racial group because susceptibility to type 2 diabetes and its CVD and CKD complications appear to differ from those in European-derived cohorts ([@B2]). The African American--Diabetes Heart Study (AA-DHS) was initiated to identify the environmental and inherited factors contributing to mortality, subclinical CVD, and bone and kidney disease in African Americans with type 2 diabetes ([@B3]). Based on rates of treatment and control of hypertension, hyperlipidemia, and hyperglycemia, AA-DHS participants appear to have similar access to health care as European Americans in contemporary reports. The cohort lacked advanced nephropathy at enrollment and was genotyped for apolipoprotein L1 gene (*APOL1*) renal-risk variants (reportedly associated with subclinical CVD) and the ancestry-informative markers available on the OMNI 5 (San Diego, CA) genome-wide association study data ([@B4]). Measures of fibroblast growth factor 23 (FGF23) were available; recent studies support an important role for this biomarker on survival ([@B5],[@B6]). The present analyses were performed to assess novel and conventional risk factors associated with mortality in this African American cohort with type 2 diabetes.

Research Design and Methods {#s2}
===========================

Study Population {#s3}
----------------

Self-reported African Americans with type 2 diabetes were recruited in the Wake Forest School of Medicine (WFSM) AA-DHS from May 2007 through August 2010 ([@B3]). Type 2 diabetes was clinically diagnosed based on disease onset after the age of 30 years in the absence of diabetic ketoacidosis and with active glucose-lowering treatment (insulin and/or oral agents), fasting glucose ≥7.0 mmol/L, nonfasting glucose ≥11.1 mmol/L, or glycosylated hemoglobin (GHb) \>6.5% (48 mmol/mol). Individuals with a known prior serum creatinine concentration ≥176.8 μmol/L were not recruited. The study was approved by the WFSM Institutional Review Board, and all participants provided written informed consent. Baseline assessments consisted of interviews for medical history, anthropometric measurements, blood pressures, and fasting blood measurements (glucose, serum creatinine, GHb, lipid panels, and a spot urine for urine albumin--to--creatinine ratio \[UACR\]). As reported, FGF23 concentrations were measured in all participants using plasma samples stored at −80°C since recruitment ([@B7]). Estimated glomerular filtration rate (eGFR) was computed using the creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation ([@B8]). Hypertension was defined based on physician diagnosis, study blood pressure \>140/90 mmHg, and/or receipt of antihypertensive medications.

Genotyping {#s4}
----------

Two single nucleotide polymorphisms in the *APOL1* G1 nephropathy risk allele (rs73885319 and rs60910145) and an indel for the G2 risk allele (rs71785313) were genotyped on the Sequenom platform using custom arrays designed at WFSM Center for Genomics and Personalized Medicine ([@B3]). African ancestry proportion was computed based on the ancestry-informative markers available on the Illumina OMNI 5 chip genome-wide association study data ([@B4]).

Vascular Imaging {#s5}
----------------

Subclinical atherosclerosis was assessed as calcified atherosclerotic plaque in the coronary arteries, carotid arteries, and infra-renal abdominal aorta using single and multidetector computed tomography systems. A standardized scanning protocol based on the National Heart, Lung, and Blood Institute Multi-Ethnic Study of Atherosclerosis (MESA) was used ([@B9]). Scoring parameters included a 90--Hounsfield unit (HU) threshold and two adjacent pixels to define the maximum calcified lesion size. Because traditional Agatston (calcium) scores add noise to the computed tomography measurement of calcified plaque compared with volume-based measures, we used the calcium mass score (milligrams of calcium) derived from the volume score and accounting for density of calcified plaque on a pixel by pixel basis ([@B10]). We used log(x+1) as the covariate in analyses for calcified plaque, where *x* represents the coronary, carotid, or aorta calcium score depending on the analysis. The addition of 1 to the calcium score made it possible to include individuals without evidence of calcification in the analyses. Quantitative coronary artery calcium mass scores were excluded from analyses in participants who had previously undergone coronary artery bypass grafting, stenting, or angioplasty; carotid scores were excluded in those with prior carotid endarterectomy.

Vital Status {#s6}
------------

Vital status was assessed through 31 December 2015 using the National Death Index. Cause of death was classified based on the primary factor reported on death certificates: 16 (23.5%) of the 54 deaths were attributed to CVD, 27.9% to cancer, 7.4% to infection, 7.4% to type 2 diabetes, and 33.8% to other causes.

Statistical Analyses {#s7}
--------------------

Demographics and laboratory characteristics of AA-DHS study participants were contrasted by survival status using Wilcoxon two-sample tests for continuous variables and χ^2^ and Fisher exact tests for binary variables. The main outcome was time to death, determined by the interval between the dates of study enrollment and death. Study participants who were known to be alive as of 31 December 2015 were censored. Cox proportional hazards models were subsequently fitted ([@B11]). Covariates were selected to limit confounding effects and ensure that reported effects were not due to other measured variables not accounted for in the model. Association results are presented for a minimally adjusted model that accounted for age, sex, and African ancestry proportion. Additional covariates were included in a subsequent model; the list of covariates varied with the predictor. For calcified atherosclerotic plaque, subsequent models were further adjusted for diabetes duration, GHb, eGFR, and UACR. Association models with kidney function and albuminuria as predictors were further adjusted for GHb, presence of hypertension, and angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB). The eGFR was included as a covariate when testing for association between UACR and time from study enrollment to death, and UACR was included when testing for association of eGFR with time to death. The model for association between African ancestry proportion and survival additionally adjusted for age, sex, BMI, diabetes duration, smoking, coronary artery calcified atherosclerotic plaque (CAC), eGFR, and UACR; the model for *APOL1* renal-risk variant association included all those covariates plus African ancestry proportion; the model for FGF23 association accounted for age, sex, BMI, diabetes duration, smoking, eGFR, UACR, hormone replacement therapy, and use of steroids. Hazard ratios (HRs) were computed for presence of the risk factor for binary predictors (e.g., presence of calcified plaque, CKD, two *APOL1* renal-risk variants, etc.) and for specific amount of change in continuous predictors (e.g., increase of 100 mg Ca^2+^ in calcified atherosclerotic plaque, 10% in African ancestry proportion, 100 mg/g in UACR, 10 mL/min/1.73 m^2^ in eGFR, and 237.8 RU/mL \[one SD change\]).

Spearman rank correlation was used to estimate the pairwise correlation between all the predictors and covariates considered in these analyses. The absolute values of the Spearman rank correlation between the predictors considered in these models were moderate, varying from a minimum of 0.01 (between age and sex) to a maximum of 0.4 (between eGFR and age). Given the correlation between these predictors, a penalized Cox regression, assuming the L1 penalty (LASSO), was then fitted with all of the predictors considered to identify the main contribution of these variables to mortality, including calcified plaque mass score in coronary and carotid arteries, UACR, eGFR, African ancestry proportion, plasma FGF23, and *APOL1* renal-risk genotypes. The LASSO model was fitted using the Cox model implemented in glmnet Package in R (<http://www.jstatsoft.org/v39/i05/>) ([@B12]). The shrinkage parameter was determined using cross-validation. All variables that had a nonzero parameter estimate in the model corresponding to the optimum λ (shrinkage parameter) were selected and used to fit a Cox proportional hazards model.

Area under the curve (AUC) computed as the area under the receiver operating characteristic (ROC) was used to compare the prognostic accuracy of a model that included established mortality risk factors (i.e., age, sex, African ancestry proportion, BMI, diabetes duration, smoking status, UACR, and CAC) to models that further incorporated *APOL1* risk and FGF23 as predictors at 1, 3, 5, and 7-year follow-up. Inference was performed under the Kaplan-Meier estimator of the censoring distribution as implemented in the R package timeROC ([@B13]). ROC curves for intermediary models (i.e., base model + *APOL1* and base model + FGF23) are also shown for completeness.

Results {#s8}
=======

The cohort included 513 unrelated African Americans with type 2 diabetes; median (25th, 75th percentile) follow-up through 31 December 2015 was 6.6 years (5.8, 7.5). During this period, 54 deaths were recorded. [Table 1](#T1){ref-type="table"} displays baseline demographic and clinical characteristics in the full sample (living and deceased subsets also provided). Participants were 55.6% female with median age 55.0 years (49.0, 62.0) at baseline, diabetes duration at enrollment 8.0 years (5.0, 13.0), and African ancestry proportion 83.2% (76.4, 88.6); 11.5% possessed two *APOL1* renal-risk variants. Medications included 63.3% of the cohort on metformin, 39.6% on insulin, and 38.8% on a sulfonylurea; none received DPP4 inhibitors, GLP-1 receptor agonists, or SGLT-2 inhibitors. In univariate analyses, male sex, lower BMI, hypertension, insulin use, and lower proportion of *APOL1* renal-risk genotypes were associated with higher mortality. Since metformin is likely more protective from CVD than sulfonylureas, we assessed differences in survival over time based on metformin use. Significant differences were not detected (HR 0.76; *P* value = 0.31).

###### 

Baseline demographic and clinical characteristics of AA-DHS cohort

  Variables                             AA-DHS cohort          *P* value                                                            
  ------------------------------------- ---------------------- ----------- ---------------------- ----- ---------------------- ---- ---------------
  Age (years)                           55.0 (49.0, 62.0)      513         55.0 (49.0, 62.0)      459   55.5 (49.2, 64.0)      54   0.42
  Female (%)                            55.6%                  513         58.2%                  459   33.3%                  54   5.0 × 10^−4^
  Smoking (%)                           59.3%                  513         58.0%                  459   70.4%                  54   0.08
  BMI (kg/m^2^)                         33.8 (29.1, 39.9)      512         34.0 (29.4, 39.9)      458   31.4 (27.7, 39.8)      54   0.05
  Diabetes duration (years)             8.0 (5.0, 13.0)        513         8.0 (4.5, 13.0)        459   8.5 (5.0, 13.8)        54   0.38
  Follow-up time (years)                6.6 (5.8, 7.5)         513         6.8 (6.1, 7.6)         459   3.3 (1.6, 4.3)         54   1.0 × 10^−30^
  Hypertension (%)                      82.5%                  513         81.0%                  459   94.4%                  54   0.01
  Systolic blood pressure (mmHg)        132.0 (121.0, 145.0)   513         132.0 (121.0, 144.0)   459   132.0 (120.0, 148.8)   54   0.67
  Diastolic blood pressure (mmHg)       78.0 (70.0, 85.0)      513         78.0 (70.0, 85.0)      459   78.0 (69.2, 84.0)      54   0.57
  Angina (%)                            14.3%                  484         13.3%                  435   22.4%                  49   0.08
  Heart attack (%)                      9.7%                   506         9.9%                   454   7.7%                   52   0.61
  Stroke (%)                            7.5%                   507         7.0%                   454   11.3%                  53   0.26
  Coronary artery bypass surgery (%)    3.5%                   513         3.3%                   459   5.6%                   54   0.39
  Coronary angioplasty (%)              12.5%                  513         12.6%                  459   11.1%                  54   0.75
  Carotid endarterectomy (%)            0.4%                   513         0.2%                   459   1.9%                   54   0.07
  Insulin use (%)                       39.6%                  513         37.3%                  459   59.3%                  54   0.002
  Metformin use (%)                     63.3%                  510         64.1%                  457   56.6%                  53   0.28
  Sulfonylurea use (%)                  38.8%                  510         39.8%                  457   30.2%                  53   0.17
  Statin use (%)                        49.0%                  512         49.8%                  458   42.6%                  54   0.32
  ACEi/ARB use (%)                      48.7%                  513         49.2%                  459   44.4%                  54   0.51
  Steroid use (oral or inhaled) (%)     7.1%                   509         7.0%                   456   7.5%                   53   0.89
  Bisphosphonate use (%)                0.2%                   510         0.0%                   457   1.9%                   53   0.003
  Hormone replacement therapy (%)       25.4%                  280         25.1%                  263   29.4%                  17   0.69
  African ancestry proportion (%)       83.2 (76.4, 88.6)      513         83.3 (76.8, 88.8)      459   82.3 (74.0, 87.6)      54   0.28
  Two *APOL1* renal-risk variants (%)   11.5%                  513         12.6%                  459   1.9%                   54   0.02

Median (25th percentile, 75th percentile) for continuous variables.

[Table 2](#T2){ref-type="table"} displays the baseline biochemical and radiographic measurements in the full sample (living and deceased subsets also provided). At baseline, median GHb was 60.7 mmol/mol (48.6, 76.0), CAC mass score 28.5 mg Ca^2+^ (1.0, 348.6), eGFR 91.3 mL/min/1.73 m^2^ (76.4, 111.3), UACR 12.5 mg/mmol (4.2, 51.2), and FGF23 224.8 pg/mL (158.1, 331.6). A total of 68 vascular beds were excluded from CAC scoring (based on 50 with angioplasty, 4 with CABG, and 14 with both) and 3 were excluded from carotid calcified plaque measures due to endarterectomy. In univariate analyses, higher FGF23, higher UACR, lower LDL cholesterol, and calcified plaque in coronary and carotid vascular beds (both amount and presence) were associated with higher mortality. A second GHb was available in 347 participants after median follow-up of 3.8 years; the median difference in GHb was −0.1 (q~1~ = −0.9, q~3~ = 0.9), suggesting that glycemic control changed little over time.

###### 

Baseline biochemical and radiological characteristics of AA-DHS cohort

  Variables                              AA-DHS cohort             *P* value                                                               
  -------------------------------------- ------------------------- ----------- ---------------------- ----- ------------------------- ---- --------------
  Fasting glucose (mmol/L)               7.4 (5.9, 9.7)            508         7.3 (5.9, 9.3)         454   8.4 (6.4, 10.5)           54   0.06
  GHb (%)                                7.7 (6.6, 9.1)            499         7.7 (6.6, 9.0)         446   7.9 (6.8, 9.6)            53   0.44
  GHb (mmol/mol)                         60.7 (48.6, 76.0)         499         60.7 (48.6, 74.9)      446   62.8 (50.8, 81.4)         53   0.44
  Serum creatinine (µmol/L)              79.6 (70.7, 97.2)         508         79.6 (70.7, 97.2)      454   88.4 (70.7, 97.2)         54   0.02
  FGF23 (RU/mL)                          112.4 (79.0, 165.8)       513         107.3 (79.0, 154.0)    459   162.3 (97.3, 362.0)       54   5.0 × 10^−4^
  FGF23 (pg/mL)                          224.8 (158.1, 331.6)      513         214.6 (158.0, 308.1)   459   324.7 (194.7, 724.0)      54   5.0 × 10^−5^
  HDL cholesterol (mmol/L)               1.2 (1.0, 1.4)            508         1.2 (1.0, 1.4)         454   1.2 (1.1, 1.4)            54   0.46
  LDL cholesterol (mmol/L)               2.7 (2.1, 3.4)            499         2.7 (2.2, 3.4)         446   2.3 (1.8, 3.1)            53   0.008
  Triglycerides (mmol/L)                 1.2 (0.9, 1.6)            508         1.2 (0.9, 1.6)         454   1.1 (0.8, 1.6)            54   0.66
  Coronary artery CP mass (mg Ca^+^)     28.5 (1.0, 348.6)         438         19.0 (0.0, 282.5)      393   187.0 (16.5, 796.5)       45   9.0 × 10^−4^
  Coronary artery CP \>10 mg Ca^+^ (%)   56.8%                     438         54.7%                  393   75.6%                     45   0.008
  Carotid artery CP mass (mg Ca^+^)      4.5 (0.0, 102.2)          503         3.5 (0.0, 92.2)        450   52.5 (0.0, 284.5)         53   0.008
  Carotid artery CP \>10 mg Ca^+^ (%)    44.9%                     503         43.1%                  450   60.4%                     53   0.02
  Aorta CP mass (mg Ca^+^)               1,033.0 (34.8, 6,465.8)   504         968 (22.0, 6,071.5)    451   1,564 (205.0, 10,759.0)   53   0.06
  Aorta CP \>10 mg Ca^+^ (%)             78.2%                     504         77.6%                  451   83.0%                     53   0.37
  Vascular beds with CP, *n*             2.0 (1.0, 3.0)            431         2.0 (1.0, 3.0)         387   2.0 (2.0, 3.0)            44   0.007
  eGFR (mL/min/1.73 m^2^)                91.3 (76.4, 111.3)        508         91.4 (76.5, 112.8)     454   89.7 (73.5, 104.6)        54   0.29
  eGFR \<60 mL/min/1.73 m^2^ (%)         9.8%                      508         9.3%                   454   14.8%                     54   0.19
  UACR (mg/mmol)                         12.5 (4.2, 51.2)          504         11.0 (4.2, 46.0)       451   40.0 (5.0, 152.0)         53   0.004
  UACR \>3.39 mg/mmol (%)                35.9%                     504         33.5%                  451   56.6%                     53   9.0 × 10^−4^

Median (25th percentile, 75th percentile) for continuous variables. CP, calcified plaque.

[Table 3](#T3){ref-type="table"} presents multivariate association analysis results for time from study enrollment to death based on presence and severity of calcified atherosclerotic plaque in three vascular beds, albuminuria, eGFR, presence of kidney disease, African ancestry proportion, *APOL1* genotype, and FGF23 concentration. In analyses assessing calcified plaque, a minimal model adjusted for age, sex, and African ancestry proportion and a subsequent model included all covariates in the minimal model plus BMI, diabetes duration, GHb, smoking, eGFR, and UACR. Presence (mass score ≥10 mg Ca^2+^) of calcified plaque in the coronary arteries and carotid arteries and total number of affected vascular beds were associated with higher mortality in the minimal, but not the full, model. Higher UACR was associated with higher mortality in the minimal model adjusting for age, sex, BMI, and African ancestry proportion and remained significant in the subsequent model that also included GHb, hypertension, and renin-angiotensin system blockade.

###### 

Multivariate risk factor association analysis results for mortality

  Predictor                                                           Change/status                                  Model 1        Model 2                                                                   
  ------------------------------------------------------------------- ---------------------------------------------- --------- ---- --------- -------------- --------------- ----- ---- ------ -------------- --------------
  Coronary artery CP, mass[^a^](#t3n1){ref-type="table-fn"}           100 (mg Ca^+^)                                 438       45   1.01      (0.99, 1.03)   0.26            422   43   1.01   (0.99, 1.03)   0.38
  Coronary artery CP, presence[^a^](#t3n1){ref-type="table-fn"}       Yes                                            438       45   2.18      (1.04, 4.57)   0.04            422   43   1.7    (0.76, 3.81)   0.19
  Carotid artery CP, mass[^a^](#t3n1){ref-type="table-fn"}            100 (mg Ca^+^)                                 503       53   1.02      (0.99, 1.05)   0.13            486   51   1.03   (0.99, 1.06)   0.10
  Carotid artery CP, presence[^a^](#t3n1){ref-type="table-fn"}        Yes                                            503       53   1.76      (0.99, 3.14)   0.05            486   51   1.72   (0.92, 3.22)   0.09
  Abdominal aorta CP, mass[^a^](#t3n1){ref-type="table-fn"}           1,000 (mg Ca^+^)                               504       53   1.02      (1.00, 1.04)   0.11            488   51   1.02   (0.99, 1.04)   0.19
  Abdominal aorta CP, presence[^a^](#t3n1){ref-type="table-fn"}       Yes                                            504       53   1.09      (0.49, 2.39)   0.83            488   51   0.69   (0.29, 1.65)   0.40
  Number of affected vascular beds[^a^](#t3n1){ref-type="table-fn"}   1                                              431       44   1.52      (1.07, 2.14)   0.02            416   42   1.32   (0.90, 1.94)   0.16
  UACR[^b^](#t3n2){ref-type="table-fn"}                               100 (mg/g)                                     504       53   2.57      (1.32, 5.03)   0.006           495   52   2.4    (1.18, 4.92)   0.02
  UACR \>30 mg/g[^b^](#t3n2){ref-type="table-fn"}                     Yes                                            504       53   2.24      (1.31, 3.83)   0.003           495   52   2.26   (1.26, 4.04)   0.006
  UACR \>300 mg/g[^b^](#t3n2){ref-type="table-fn"}                    Yes                                            504       53   2.3       (1.03, 5.14)   0.04            495   52   1.89   (0.78, 4.54)   0.16
  eGFR[^b^](#t3n2){ref-type="table-fn"}                               10 (mL/min/1.73 m^2^)                          508       54   0.9       (0.77, 1.06)   0.22            499   53   0.9    (0.76, 1.07)   0.24
  eGFR \<60 mL/min/1.73 m^2^[^b^](#t3n2){ref-type="table-fn"}         Yes                                            508       54   1.94      (0.76, 4.94)   0.17            499   53   2.12   (0.81, 5.51)   0.13
  CKD[^b^](#t3n2){ref-type="table-fn"}                                Yes                                            504       53   1.85      (0.91, 3.73)   0.09            495   52   1.79   (0.84, 3.80)   0.13
  African ancestry proportion[^c^](#t3n3){ref-type="table-fn"}        10%                                            512       54   0.89      (0.68, 1.15)   0.37            429   44   0.83   (0.63, 1.11)   0.21
  *APOL1* renal-risk variants[^d^](#t3n4){ref-type="table-fn"}        Two risk variants                              512       54   0.13      (0.02, 1.01)   0.05            429   44   0.16   (0.02, 1.17)   0.07
  Plasma FGF23[^e^](#t3n5){ref-type="table-fn"}                       237.8 RU/mL[^f^](#t3n6){ref-type="table-fn"}   513       54   1.69      (1.43, 1.98)   3.3 × 10^−10^   503   53   1.74   (1.44, 2.09)   6.9 × 10^−9^

CP, calcified plaque.

^a^Model 1 adjusts for age, sex, and ancestry proportion. Model 2 adjusts for model 1 + BMI, diabetes duration, GHb, smoking, eGFR, and UACR.

^b^Model 1 adjusts for age, sex, BMI, and ancestry. Model 2 adjusts for model 1 + GHb, hypertension, and renin-angiotensin system blockade. CKD reflects eGFR \<60 mL/min/1.73 m^2^ and/or UACR \>300 mg/g.

^c^Model 1 adjusts for age, sex, BMI, and diabetes duration. Model 2 adjusts for model 1 + smoking, eGFR, UACR, and coronary artery CP.

^d^Model 1 adjusts for age, sex, ancestry, and diabetes duration. Model 2 adjusts for model 1 + BMI, smoking, eGFR, UACR, and coronary artery CP.

^e^Model 1 adjusts for age, sex, and ancestry. Model 2 adjusts for model 1 + BMI, diabetes duration, smoking, eGFR, hormone replacement therapy, and steroids (118.6 RU/mL value corresponds to a change of 0.5 × SD in FGF23 concentration).

^f^237.8 RU/mL is equivalent to 473.2 pg/mL.

[Table 3](#T3){ref-type="table"} presents association results between mortality and the novel risk factors African ancestry proportion, *APOL1* genotypes, and FGF23. Higher plasma FGF23 concentration was strongly associated with higher mortality after adjusting for age, sex, and African ancestry (minimal model) and in the subsequent model that also included BMI, diabetes duration, smoking, eGFR, hormone replacement therapy, and use of steroids (HR 1.74 \[95% CI 1.44--2.09\]; *P* = 6.9 × 10^−9^). For each 237.8 RU/mL increase in FGF23 concentration, 74% higher mortality was seen. Presence of the *APOL1* renal-risk genotype (two *APOL1* renal-risk variants) was associated with lower mortality in the minimal model (*P* = 0.05), with a trend in the full model that also included age, sex, African ancestry, diabetes duration, BMI, smoking, eGFR, UACR, and CAC (HR 0.16 \[95% CI 0.02--1.17\]; *P* = 0.07). African ancestry proportion was not associated with mortality in either model.

Results of the LASSO multivariate model are presented in [Table 4](#T4){ref-type="table"}. Predictors of mortality included sex (male risk, *P* = 2.0 × 10^−4^), *APOL1* risk genotypes (absence of two *APOL1* renal-risk variants risk, *P* = 0.02), and plasma FGF23 concentration (higher risk, 1.4 × 10^−7^); trends were observed for effects of diabetes duration (*P* = 0.07), number of affected vascular beds (*P* = 0.07), and UACR (*P* = 0.11). CAC, eGFR, smoking, BMI, and GHb were not significant predictors of mortality in this analysis.

###### 

Multivariate model with nonzero predictors of mortality in the LASSO model

  Predictor                          LASSO estimate   Change/status   HR     95% CI         *P* value
  ---------------------------------- ---------------- --------------- ------ -------------- --------------
  Age                                0                ---             ---    ---            ---
  Sex (male)                         −0.59            1               4.17   (1.96, 9.09)   0.0002
  BMI                                0                ---             ---    ---            ---
  Diabetes duration                  0.16             4               1.13   (0.99, 1.28)   0.07
  Smoking status                     0.01             1               1.31   (0.65, 2.64)   0.46
  Coronary artery CP, mass           0                ---             ---    ---            ---
  Carotid artery CP, mass            0                ---             ---    ---            ---
  Abdominal aorta CP, mass           0                ---             ---    ---            ---
  Number of affected vascular beds   0.24             1               1.42   (0.98, 2.06)   0.07
  UACR                               0.19             100             1.94   (0.86, 4.41)   0.11
  eGFR                               0                ---             ---    ---            ---
  CKD                                0                ---             ---    ---            ---
  African ancestry proportion        −0.11            10              0.81   (0.60, 1.08)   0.15
  *APOL1* renal-risk variants        −0.34            1               0.07   (0.01, 0.69)   0.02
  Plasma FGF23                       0.39             238             2.1    (1.59, 2.78)   1.4 × 10^−7^
  GHb                                0                ---             ---    ---            ---

The LASSO and the final Cox regressions were fit based on a sample size of 416 individuals and 42 deaths. CP, calcified plaque.

[Figure 1](#F1){ref-type="fig"} displays four ROC plots for predicted survival at 1, 3, 5, and 7 years in a model including age, sex, ancestry, BMI, diabetes duration, smoking, UACR, and CAC. *P* values compare the AUC of the models with these covariates to the AUC also including FGF23 and *APOL1* genotypes; they reveal significantly improved prognostic accuracy of the model at all time points after 1-year follow-up. For example, the AUC improved from 0.72 to 0.80 at 7 years (*P* = 2.1 × 10^−4^).

![Comparison of ROC curves for models with and without *APOL1* renal-risk genotypes and FGF23. *A*: Predicted survival at 1 year. *B*: Predicted survival at 3 years. *C*: Predicted survival at 5 years. *D*: Predicted survival at 7 years. Model 1 (M1) includes age, sex, African ancestry proportion, BMI, diabetes duration, smoking status, UACR, and CAC. *P* values compare the AUC of the full model that includes all the covariates in model 1 plus *APOL1* risk and FGF23 to model 1.](dc170820f1){#F1}

Conclusions {#s9}
===========

This study assessed factors associated with mortality in an African American cohort with type 2 diabetes that was intensively phenotyped for subclinical CVD, nephropathy, and associated risk factors. Considering the known effects of subclinical atherosclerosis, kidney disease, glycemic control, and smoking, novel relationships were identified between higher plasma FGF23 concentrations and absence of *APOL1* renal-risk genotypes with higher mortality. The AA-DHS is a unique cohort of African Americans with relatively preserved kidney function, access to health care based on achieved blood pressure, lipid levels, and blood sugars, and linkage to the National Death Index ([@B3]). Traditional CVD risk factors were associated with higher mortality in this cohort, including male sex, hypertension, presence of clinical and subclinical CVD, and kidney disease ([@B14]--[@B16]). The novel finding of association between increasing plasma FGF23 concentrations and higher mortality was robust, observed in the final multivariate model ([Table 4](#T4){ref-type="table"}). In addition, significant association between *APOL1* non--renal-risk genotypes and higher mortality was independent from severity of albuminuria and degree of kidney function in this model.

African Americans with and without diabetes are at higher risk than European Americans for major CVD events and higher mortality rates ([@B17],[@B18]). However, many reports on African Americans included individuals without access to adequate health care and with suboptimal control of conventional CVD risk factors ([@B19],[@B20]). Lack of access to health care likely confounds many outcome studies in minority populations. In support of this concept, multiethnic studies in populations with equivalent access to health care demonstrated marked reductions in risk of myocardial infarction and lower mortality in African Americans than European Americans ([@B20]--[@B23]). This contrasts with the increased risk of CVD and higher mortality in African Americans than in the general population. Dramatically lower rates of subclinical CVD, typically assessed as calcified atherosclerotic plaque, are seen in African Americans relative to European Americans ([@B24]--[@B29]). This is observed in populations with and without diabetes and despite the presence of more severe conventional CVD risk factors in African Americans. MESA and the AA-DHS reported that higher proportions of African ancestry were associated with lower levels of CAC ([@B30],[@B31]). It is likely that the biologically protective effect of African ancestry on CVD can be overwhelmed by the environmental factor suboptimal access to health care.

A novel finding was the positive association between plasma FGF23 concentrations and mortality in this cohort lacking advanced kidney disease. FGF23 is an osteocyte-derived phosphaturic hormone that plays a key role in CKD--mineral and bone disorder. In addition to suppressing parathyroid hormone secretion, FGF23 downregulates proximal tubule sodium phosphate cotransporter Na/Pi IIa and IIc and inhibits renal calcitriol synthesis to achieve phosphate homeostasis in early stages of CKD ([@B32]). FGF23 is reproducibly associated with an elevated risk of CVD and death in cohorts with moderate to severe CKD. A prospective study of individuals from the Chronic Renal Insufficiency Cohort (CRIC) with moderate CKD found FGF23 to independently predict mortality ([@B33]). Likewise, elevated FGF23 levels have been associated with higher mortality in incident hemodialysis patients ([@B34]). Epidemiological studies reveal positive associations between FGF23 and CAC, thoracic, and abdominal calcified plaque including in a prior AA-DHS report ([@B7]), but this finding was not replicated in CRIC or MESA ([@B35],[@B36]).

Levels of FGF23 rise early in the course of CKD and may be one of the earliest biomarkers of CKD--mineral and bone disorder. In cohorts with mild CKD, elevated circulating FGF23 levels have demonstrated adverse CVD outcomes in predominantly non--African American cohorts ([@B37]--[@B39]). The present results extend this observation to an African American sample with normal to mildly reduced kidney function. In addition, the association was robust to adjustment for eGFR and albuminuria, suggesting that FGF23 effects are independent from severity of kidney disease. Findings extend our prior work on FGF23 based on the addition of mortality data through calendar year 2015 and inclusion of CAC and *APOL1* as covariates in the model ([@B7]).

Participants who had two *APOL1* renal-risk variants (defining the renal-risk genotype) also had lower mortality rates than those with fewer than two risk variants. *APOL1* is not associated with kidney disease in patients with diabetes ([@B3]). Although *APOL1* renal-risk variants were reproducibly associated with lower levels of calcified plaque in the Jackson Heart Study and AA-DHS, as well as with less severe cerebral small vessel disease, associations with CVD remain controversial ([@B40]). The present results support *APOL1* renal-risk genotype association with lower mortality after accounting for the competing effects of age, sex, BMI, diabetes duration, smoking, African ancestry proportion, UACR, and FGF23.

The AA-DHS is focused on the understudied African American population; it has strengths and limitations. Strengths include the relatively large population-based cohort with type 2 diabetes, extensive CVD and renal phenotypes, and long-term follow-up. One limitation is that all causes of death were assessed in this report. This related to use of the National Death Index. Death certificates revealed that 23.5% of the 54 deaths were attributed to CVD; however, inaccuracies exist with death certificates and we were unable to adjudicate cause of death. Analyses used baseline GHb measures, which remained stable during 3.8-year median follow-up in the majority of participants. However, longer-term changes in glycemic control in the full cohort could not be assessed. A potential drawback of using a LASSO multivariate model is that it typically selects only one predictor from a group of correlated predictors. This could explain why the parameter estimate associated with CAC was shrunken to 0 in the presence of other, possibly stronger, predictors of death in this data set. Few cohorts contain African Americans with type 2 diabetes who lack nephropathy and have measures of CAC and FGF23; as such, replication in a similar population may prove challenging. We note that smoking did not associate with mortality in this report. This paradoxical observation likely relates to limitations in the sample size and duration of follow-up. Finally, current findings are limited to African Americans with type 2 diabetes. Results cannot be extrapolated to other populations or those without diabetes. We could not assess effects of FGF23 in European American DHS participants because plasma samples were lost after a freezer malfunction; European populations also lack *APOL1* risk variants.

Analyses in a large cohort of African Americans with type 2 diabetes at high risk for CVD confirm that hypertension, male sex, lower BMI, subclinical atherosclerosis, and albuminuria were associated with higher mortality. In addition and independent of kidney function, higher plasma FGF23 concentrations and absence of *APOL1* renal-risk genotypes were associated with higher mortality rates. Roles for measuring FGF23 levels and *APOL1* genotypes in clinical practice to aid in risk prediction remain unclear. The consistent association between FGF23 and mortality suggests that this biomarker is a risk factor that warrants measurement; herein, we extend this observation to the African American population with diabetes. Additional replication studies will be required to assess the association with *APOL1*, and this effect would only be relevant in populations with recent African ancestry, such as African Americans. Higher FGF23 levels and absence of *APOL1* risk genotypes had previously been associated with calcified atherosclerotic plaque (subclinical atherosclerosis). Although reports that show higher mortality rates and rates of myocardial infarction in African Americans relative to European Americans may have been confounded by suboptimal access to health care, the AA-DHS cohort appears to have had similar access to health care as European Americans in most contemporary reports. Mechanisms whereby FGF23 and *APOL1* renal-risk variants impact subclinical atherosclerosis and mortality remain to be identified.
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